Dr. Do-Youn Oh, MD
Claim this profileSeoul National University Hospital
Studies Adenocarcinoma
Studies Cancer
24 reported clinical trials
48 drugs studied
Area of expertise
1Adenocarcinoma
Stage IV
HER2 positive
Stage III
2Cancer
HER2 positive
Stage IV
Stage III
Clinical Trials Do-Youn Oh, MD is currently running
Tinengotinib
for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Recruiting2 awards Phase 3
MR-Guided Radiation Therapy
for Stomach Cancer
Gastric cancer is a global health issue as the world's fifth most common malignancy and third leading cause of cancer mortality, respectively. Preoperative radiation therapy may improve overall survival (OS) but is seldom used. There is precedent for preoperative chemoradiation, as it is the standard of care for esophageal and gastroesophageal junction tumors. However, reluctance of physicians to prescribe preoperative radiation therapy in gastric cancer may be due to the large treatment fields necessary to account for stomach motion. Adaptive radiation therapy may permit decreased field sizes and more accurate dose delivery. In traditional CT based radiation delivery the same radiation plan is delivered each day without assessment of inter-fraction or intra-fraction motion. Adaptive radiation therapy permits the physician to contour the unique anatomy daily to generate a new plan to account for day to day organ motion. Real-time MR imaging is also used during the treatment so that radiation is only delivered when the tumor is within the pre-specified target area. Thus, adaptive radiation therapy may overcome traditional barriers of radiation delivery in gastric cancer and improve oncologic outcomes.
Recruiting1 award Phase 212 criteria
More about Do-Youn Oh, MD
Clinical Trial Related2 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Do-Youn Oh, MD has experience with
- Capecitabine
- Gemcitabine
- ZW25 (Zanidatamab)
- Tucatinib
- Oxaliplatin
- Cisplatin
Breakdown of trials Do-Youn Oh, MD has run
Adenocarcinoma
Cancer
Biliary Tract Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Do-Youn Oh, MD specialize in?
Do-Youn Oh, MD focuses on Adenocarcinoma and Cancer. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are HER2 positive.
Is Do-Youn Oh, MD currently recruiting for clinical trials?
Yes, Do-Youn Oh, MD is currently recruiting for 8 clinical trials in Seoul Other. If you're interested in participating, you should apply.
Are there any treatments that Do-Youn Oh, MD has studied deeply?
Yes, Do-Youn Oh, MD has studied treatments such as Capecitabine, Gemcitabine, ZW25 (Zanidatamab).
What is the best way to schedule an appointment with Do-Youn Oh, MD?
Apply for one of the trials that Do-Youn Oh, MD is conducting.
What is the office address of Do-Youn Oh, MD?
The office of Do-Youn Oh, MD is located at: Seoul National University Hospital, Seoul, Other 03080 Korea, Republic of. This is the address for their practice at the Seoul National University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.